Project: COMPETE2030-FEDER-00878200- HOPE

Project name:	HOPE - Targeting B-MyB oncogene via Aptamer conjugates: a promising strategy against lung cancer
Project code:	COMPETE2030-FEDER-00878200- HOPE
Intervention Region:	Norte, Centro
Proposing institution/Lead promoter/Coordinating entity:	Universidade da Beira Interior
Partner(s)/Co-promoter(s)/Participating institution(s):	Instituto Nacional de Investigação Agrária e Veterinária, I. P.; Faculdade de Medicina da Universidade do Porto; IPATIMUP - Instituto de Patologia e Imunologia Molecular da UP
Start date:	2025-01-01
Completion date:	2027-12-31

Objectives, activities and expected/achieved results

LC is one of the most challenging human tumors. Tobacco smoking is associated with an increased risk and the mortality related to LC continues to increase. Current projections estimate that this tumor will be the main cause of cancer death in the next decades unless substantial progress is made. Altogether, there is a dramatic need to improve molecularly-based therapy which can signifi cantly impact tumor treatment and patient survival. B-MYB, which acts as a transcription factor, is typically expressed in dividing cells and plays a crucial role in cell proliferation and control of cellular differentiation. It has a vital role in guiding the regulation of apoptosis and tumor progression in LC. A study found that B-MYB overexpression was related to shorter overall survival in LC patients. Due to the undruggable profi le of the B-MYB transcription factor, it is necessary to develop new and effi cient therapeutic approaches.

Recommend this page Top

Copyright 1996-2025 © Instituto de Ciências Biomédicas Abel Salazar I Terms and Conditions I Acessibility I Index A-Z
Page created on: 2025-09-24 at 18:32:51 | Privacy Policy | Personal Data Protection Policy | Whistleblowing | Electronic Yellow Book